NEW ORLEANS — PhaseBio, a small biotechnology firm based in Malvern, Pa., is not loved by investors. Its shares are down 25 percent from their October 2018 initial public offering, and the company has a market capitalization of just $89 million. So it’s a bit of a surprise to see the company’s experimental drug highlighted in the New England Journal of Medicine.

The study, also being presented here at the annual meeting of the American College of Cardiology, tested PhaseBio’s drug, PB2452, as a way to reverse the effects of Brilinta, an AstraZeneca drug that is used to prevent blood from clotting in heart patients, including those who have received stents to prop open clogged arteries.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy